Abstract-Understanding the complex dynamics between the tumor cells and the host immune system will be key to improved therapeutic strategies against cancer. We propose an ODE-based mathematical model of both the tumor and immune system and how they respond to inactivation of the driving oncogene. Our model supports experimental results showing that cellular senescence of tumor cells is dependent on CD4+ T helper cells, leading to relapse of tumors in immunocompromised hosts.
I. INTRODUCTION
The immune system plays a major role in controlling tumor growth. AIDS and post-transplant patients with immunodeficiencies have been shown to have an increase in various types of tumors. The importance of the immune system has also been demonstrated in pre-clinical mouse models that are genetically engineered with various immunodeficiencies.
In particular, the CD4+ T cells play a significant role [1, 2] . Previously, CD8+ T killer cells were thought to be the sole direct effector cells that caused cell death. However, more recently, it has become clear that CD4+ T helper cells in the absence of CD8+ cells are able to cause significant tumor regression (by recruiting macrophages).
The focus of this work is on the inactivation of the MYC oncogene. The myc family of proto-oncogenes is believed to be involved in the genesis of many human malignancies [3] . Bernard Weinstein first coined the term 'oncogene addiction' in 1997 to represent the phenomenon whereby even the brief inactivation of a single oncogene may lead to sustained tumor regression providing a weakness for molecularly targeted therapy to exploit [4] . Hence it is an Achilles' heel for cancerous tumors [5] . An oncogene is a gene that is stuck in a state of constant activity and is the genesis of cancer. It has been shown that inactivation of an oncogene alone leads to tumor regression. The challenge is in the prevention of relapse of the tumor. This paper combines a model of the tumor and the immune system as it relates to oncogene inactivation.
II. METHODS
Previously, we developed the model shown in Fig. 1 . It is capable of representing the various cellular programs in response to oncogene inactivation. The shortcomings are that the immune system has been modeled with system parameters that have one value under an intact immune system and another value in an immunocompromised host. This allows us to replicate experimental results (e.g., the suppression of tumor relapse with an intact immune system, CD4+ cells in particular) but does not shed light on the mechanisms at play as regards the immune system.
We have started incorporating other published models of tumor-immune interactions. However, these have some shortcomings as well. For example, we have built upon the model in [6] , which assumes that all interactions are mediated through effector cells (CD8+ T killer cells). However our data [1] demonstrate that CD4+ T helper cells are the critical component of tumor regression. Others have shown that the effect of CD4+ T helper cells is mediated primarily through macrophages. Another shortcoming is that most models of tumor-immune interactions model the tumor as one uniform type of cell. Our data demonstrates otherwise. In particular, tumor cells are known to go through various states such as senescence, differentiation, apoptosis, etc., leading to very different fates for each cell. Hence our work here integrates (1) our previous multi-state tumor model, (2) the immune model in [6] , and (3) our changes to the immune model to account for non-CD8+ dependent pathways for tumor cell kill.
A. Tumor Model with Multiple Cellular Programs
Our model of tumor growth/regression kinetics incorporates cell intrinsic mechanisms (apoptosis, proliferative arrest, differentiation/dormancy) and immunemediated cell extrinsic mechanisms (senescence). We have a complex model of the tumor with 'MYC on', 'MYC off', apoptosis, proliferating, differentiated, and senescent states ( Fig. 1) .
In our experimental model, we are able to control the expression of transgenic MYC using the tetracycline system. 978-1-4577-0216-7/13/$26.00 ©2013 IEEEmodel [7] . This represents the eventual relapse of tumors even after treated with directed therapeutics.
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B. Immune System Model
We extensively model the immune system by adapting the model from [6] . See What is novel about our application of [6] is an explicit representation of the direct role of CD4+ T helper cells through macrophages. We show that an intact immune system is necessary to completely eliminate tumors (Fig. 3) .
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Time affer MYC inactivat ion (days) Particularly, even in the absence of CDS+ T cells (effector cells), tumor regression can be achieved [1] , which is impossible with the original model of [6] . The helper cells play a critical central role in developing immune responses by activating antigen-specific effector cells as well as stimulating the innate immune system against cancer [S] . The CD4+ T helper cells increase the rate of the transition of the tumor cells in the 'MYC off state to 'Senescence' and macrophages mediate clearance of senescent tumor cells [9] .
C. Combined Tumor-Immune Model
The implementation of the tumor and immune system model includes a series of ODEs (Fig. 4) Our primary modification to [6] was the addition of CD4+ dependent macrophage (M) recruitment. These tumorassociated macrophages then clear senescent tumor cells. Many of the system parameter values in the equations from Fig. 4 , particularly those from [6] are estimated from the literature while several others are chosen by hand to match simulated tumor trajectories to empirical data.
III. RESULTS
The simulations from our model recapitulate features in the tumor kinetics measured from in vivo experimental data from mouse models. We also provide an explanation for the mechanism through which the immune system brings about sustained tumor regression.
In particular, we add the effect of the CD4+ T helper cells through the macrophages. We show the population of the immune cells over time in the top plot of Fig. 5 and the concentration of the cytokines over time in the middle plot of Fig. 5 . The adaptive immune system has a time constant of response of approximately 3-7 days. Macrophage recruitment approaches peak by approximately 10 days. The cytokine (TGF-, IL-2, IL-10) response has similar dynamics.
In the presence of an intact immune system, we achieve sustained tumor regression (not shown), however, in an immune-compromised host, there is relapse (Fig. 5, bottom  plot) . Similar to our experimental data, the initial tumor response is proliferative arrest with the majority of tumor cell death following day 4 (after oncogene inactivation). In the absence of CD4+ cells, tumor relapse is seen by day 20-25 although the growing escaped tumor cell population begins growth almost immediately following oncogene inactivation but is not apparent until it surpasses the non-escaped tumor cell population. 
IV. CONCLUSION
Our hybrid tumor-immune model involves the major biological features involved in the CD4+ dependent response to oncogene inactivation.
We explain the mechanisms involved in host-tumor interactions specifically as it relates to oncogene inactivation. We find that in an intact immune system (which is modeled through the specified parameters for the immune system), there is continued regression. An important factor leading to sustained regression is the action of the macrophages on senescent cells.
Our future research is directed towards a sensitivity analysis for the parameters of the model as well as further in vivo validation of our model on mouse models.
